- Home
- AVTX vs CRVO Comparison
AVTX vs CRVO Comparison
Compare AVTX & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- CRVO
- Stock Information
- Founded
- AVTX 2011
- CRVO 2001
- Country
- AVTX United States
- CRVO United States
- Employees
- AVTX N/A
- CRVO N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- CRVO Health Care
- Exchange
- AVTX Nasdaq
- CRVO Nasdaq
- Market Cap
- AVTX 88.4M
- CRVO 95.4M
- IPO Year
- AVTX 2015
- CRVO N/A
- Fundamental
- Price
- AVTX $4.41
- CRVO $9.80
- Analyst Decision
- AVTX Strong Buy
- CRVO Strong Buy
- Analyst Count
- AVTX 7
- CRVO 8
- Target Price
- AVTX $34.33
- CRVO $25.43
- AVG Volume (30 Days)
- AVTX 69.6K
- CRVO 1.5M
- Earning Date
- AVTX 05-12-2025
- CRVO 05-13-2025
- Dividend Yield
- AVTX N/A
- CRVO N/A
- EPS Growth
- AVTX N/A
- CRVO N/A
- EPS
- AVTX N/A
- CRVO N/A
- Revenue
- AVTX $441,000.00
- CRVO $9,737,974.00
- Revenue This Year
- AVTX N/A
- CRVO N/A
- Revenue Next Year
- AVTX N/A
- CRVO N/A
- P/E Ratio
- AVTX N/A
- CRVO N/A
- Revenue Growth
- AVTX N/A
- CRVO 36.29
- 52 Week Low
- AVTX $4.44
- CRVO $1.80
- 52 Week High
- AVTX $17.49
- CRVO $25.69
- Technical
- Relative Strength Index (RSI)
- AVTX 29.58
- CRVO 55.40
- Support Level
- AVTX $4.59
- CRVO $9.03
- Resistance Level
- AVTX $5.85
- CRVO $10.89
- Average True Range (ATR)
- AVTX 0.85
- CRVO 1.90
- MACD
- AVTX -0.21
- CRVO -0.29
- Stochastic Oscillator
- AVTX 2.41
- CRVO 32.37
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.